Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown. In this retrospective cohort study, we collected 32,864 hospitalized COVID-1...
Saved in:
Main Authors: | Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225001671 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
by: Haiyu Wang, et al.
Published: (2025-01-01) -
Accessible moderate-to-severe obstructive sleep apnea screening tool using multidimensional obesity indicators as compact representations
by: Xiaoyue Zhu, et al.
Published: (2025-02-01) -
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01) -
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
by: Jamie L. Lim, et al.
Published: (2025-02-01) -
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01)